Propanc Biopharma (NASDAQ:PPCB) Shares Up 0.8% – What’s Next?

Propanc Biopharma Inc (NASDAQ:PPCB)’s share price was up 0.8% on Thursday. The stock traded as high as $1.99 and last traded at $1.8550. Approximately 21,769 shares were traded during trading, a decline of 45% from the average session volume of 39,323 shares. The stock had previously closed at $1.84.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Propanc Biopharma Trading Up 0.8%

The stock has a market capitalization of $1.17 million, a PE ratio of -0.01 and a beta of 3.55. The business’s 50 day moving average is $4.73 and its 200 day moving average is $20.69.

Propanc Biopharma (NASDAQ:PPCB) last issued its earnings results on Friday, September 25th. The company reported ($17.74) earnings per share (EPS) for the quarter.

About Propanc Biopharma

Propanc Biopharma, Inc. (NASDAQ:PPCB) is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors, including pancreatic, ovarian and colorectal cancers. The company’s research is based on proenzyme therapy, an approach intended to selectively target cancer cells and cancer stem cells while limiting tumor growth, recurrence and metastasis. Propanc’s lead investigational product is PRP, also referred to as PRP-100, an intravenous formulation comprising the naturally occurring digestive proenzymes trypsinogen and chymotrypsinogen.